Fast, accurate and cost-effective diagnoses to tackle respiratory infections

July 29, 2015, CORDIS
Fast, accurate and cost-effective diagnoses to tackle respiratory infections

ecently published in the Annals of Internal Medicine, the study found that starting anti-HIV treatment within two weeks of TB being diagnosed improved survival rates among patients with both infections who had very low immune-cell counts. Those with strong immune systems, however, appeared to benefit from waiting until after the end of the six-month TB treatment before initiating anti-HIV therapy. The study recommended updating guidelines to take these findings into account.

Treating HIV and TB simultaneously has proved challenging for a number of reasons, including the requirement for patients to take multiple pills, as well as drug to drug interactions and overlapping side effects. This particular study sought to investigate the optimal timing of HIV treatment initiation in light of recent clinical trials.

This is one example of how the RID-RTI project, which began in July 2012, has contributed to improving the survival chances of patients with Respiratory Tract Infections (RTIs). These infections are caused by a variety of bacterial, viral and fungal pathogens and are major causes of morbidity and mortality in adults and children worldwide.

RTIs such as TB and pneumonia are a truly global health problem. In 2013 there were an estimated 9 million new cases of TB, with between 1.3 and 1.5 million associated deaths. More people in the developing world contract TB because of poor immune systems largely due to high rates of HIV infection and the development of AIDS.

According to the World Health Organisation (WHO), pneumonia is the leading cause of death in children globally, killing an estimated 1.4 million children under the age of five each year.

One reason why RTIs continue to proliferate is that they are so difficult to diagnose quickly and accurately. Current tests are intensely time consuming, and as a result, patients presenting RTI symptoms are often treated uniformly with antibiotics without the causative microorganism being accurately identified. This can lead to the inappropriate use of antibiotics, which in turn increases patient morbidity and mortality.

In order to address this issue, the RID-RTI project – built around a consortium of SMEs, universities and hospitals from Finland, France, Ireland and the UK – has sought to develop a rapid molecular diagnostic test capable of identifying a large range of microorganisms responsible for RTIs. This will lead to more appropriate therapies applied after the very first consultation.

The test, which is being built on a simple 'sample-in, answer-out' diagnostic platform, will be cost-effective and user friendly, and will be capable of delivering results in under two hours. This sets it apart from current diagnostics technology. It is hoped that the speed and accuracy of the platform will revolutionise how RTIs are treated.

Furthermore, an exploitation plan is now being developed to ensure that project results can be translated into commercial products. The ultimate objective is for new cost effective, user-friendly products to be routinely used in hospitals. The RID-RTI project is due for completion at the end of December 2015.

Explore further: Early HIV treatment improves survival in some patients with newly diagnosed TB

More information: For further information please visit RID-RTI: www.rid-rti.eu/rid-rti/home_page

Related Stories

Early HIV treatment improves survival in some patients with newly diagnosed TB

July 9, 2015
Starting anti-HIV treatment within two weeks of the diagnosis of tuberculosis, or TB, improved survival among patients with both infections who had very low immune-cell counts, according to an analysis by researchers at the ...

Diabetes—Tuberculosis link found in Australia

July 27, 2015
A 20-year study by James Cook University scientists has found a strong link between diabetes and tuberculosis in tropical Australia.

A low-cost urine test for tuberculousis that could save thousands of lives

September 29, 2014
Tuberculosis (TB) is an infectious bacterial disease that affects the lungs and kills nearly two million people every year. Most of these deaths occur among the poorest communities in the world, where access to medical care ...

Scientists to study the role genes play in treating tuberculosis

October 25, 2012
The University of Liverpool has been awarded funding to determine whether differences in our genes determine how patients respond to drugs used to treat Tuberculosis (TB) in Sub-Saharan Africa.

Fluoroquinolones halt multidrug-resistant-TB in contacts

July 24, 2015
(HealthDay)—For contacts of individuals with multidrug-resistant tuberculosis (MDR-TB), fluoroquinolone (FQN) therapy is associated with health system savings and reduced mortality, according to a study published in the ...

Recommended for you

Researchers seek vaccine for 'traveler's diarrhea'

September 25, 2018
Every year, millions of people have vacations and business trips ruined when they succumb to "traveler's diarrhea" during their journeys. A major cause of traveler's diarrhea is bacteria called Enterotoxigenic E. coli, or ...

Experimental vaccine shows promise in preventing TB

September 25, 2018
(HealthDay)—Tuberculosis remains the most lethal of infectious diseases worldwide, killing more than 1.6 million people a year. But researchers say a new vaccine might prevent half of full-blown illnesses in infected people ...

Many doctors in India miss TB signs: study

September 25, 2018
Many private sector doctors in India miss the signs of tuberculosis and therefore provide patients inadequate treatment, according to a new study published Tuesday involving people hired to act out the symptoms.

New way of determining treatment for staph infections cuts antibiotic use

September 25, 2018
Using a clinical checklist to identify eligible patients, doctors were able to shorten the antibiotic duration for patients with uncomplicated staphylococcal bloodstream infections by nearly two days, Duke Health researchers ...

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.